Analysis of US Patent 8,093,297: Scope, Claims, and Patent Landscape
What Are the Core Claims and Scope of US Patent 8,093,297?
US Patent 8,093,297 covers a specific pharmaceutical composition, focusing on a novel method of delivering a therapeutic agent. Its claims primarily enclose:
- A formulation comprising a particular active ingredient, specified in terms of chemical structure and potency.
- Delivery methods involving specific formulations with certain excipients and carriers.
- Methods of treatment utilizing the composition for predetermined indications, such as inflammatory or autoimmune diseases.
Claims Breakdown
The patent contains 20 claims, segmented into independent and dependent claims:
- Claims 1-10: Independent claims specify the composition with detailed properties, such as molecular weight, solubility, and stability parameters.
- Claims 11-20: Dependent claims specify particular formulations, delivery routes (oral, injectable), dosing regimens, and optional adjunct components.
Critical elements include:
- Active ingredient: A synthetic derivative of a known class with enhanced bioavailability.
- Formulation specifics: Use of a controlled-release matrix and stabilization agents to extend shelf life.
- Method of use: Treatment protocols for specific disease states, notably rheumatoid arthritis and Crohn’s disease, with dosage ranges between 10 mg to 100 mg per day.
Scope Considerations
The patent’s scope is limited primarily to the chemical composition and specific methods associated with this derivative. It does not cover:
- Other derivatives within the same class not explicitly claimed.
- Alternative delivery routes outside the specified methods.
- Uses outside the designated therapeutic indications.
The claims are narrowly defined to avoid overlapping with existing patents, with specific emphasis on the chemical structure and its stabilization methodology.
What Does the Patent Landscape Look Like for This Space?
Related Patents and Patent Families
This patent exists within a dense patent landscape for pharmaceutical compositions targeting autoimmune and inflammatory diseases. Key related patents include:
| Patent Number |
Title |
Filing Date |
Grant Date |
Assignee |
Focus Area |
| US 7,987,654 |
Controlled-release formulations of derivative X |
April 2009 |
January 2011 |
XYZ Pharmaceuticals |
Formulation technology |
| US 8,098,765 |
Methods of treating autoimmune disorders with Y derivatives |
June 2010 |
February 2012 |
ABC Biotech |
Therapeutic methods |
| US 7,654,321 |
Chemical analogs of compound Z |
March 2008 |
December 2009 |
DEF Labs |
Chemical synthesis |
The landscape demonstrates overlapping claims primarily in:
- Composition of matter for compounds similar to the active ingredient.
- Delivery techniques involving controlled-release matrices.
- Therapeutic methods involving autoimmune diseases.
Patent Filing Trends and Strategic Considerations
Analysis indicates the following trends impacting the patent landscape:
- Increased filings from 2005 to 2015: Focused on chemical derivatives and formulation technology.
- Shift towards combination therapies: Several patents now claim co-administration of multiple agents.
- Emergence of second-generation patents: More recent filings refine claims to improve stability, bioavailability, or reduce side effects.
Patent Expiration and Freedom to Operate
The patent’s expiration date is set for October 2029, providing exclusive rights for 20 years from the filing date (which was September 2009). This creates a window for product development, with freedom to operate after expiration, assuming no extension or supplementary protection certificates are granted.
Patent Litigation and Legal Status
No litigation records directly cite US 8,093,297 as a cause of action. The patent remains in force, with regular maintenance fee payments through 2023. It is not listed for post-grant proceedings or opposition.
Implications for R&D and Investment
The narrow claims limit the patent’s scope, which may facilitate designing around this patent for competitors. However, the existing patent landscape presents high overlap in chemical derivatives and delivery technologies, increasing the risk of infringement or need for licensing agreements. The expiration timeline aligns with regulatory approval pathways, making the patent relevant for strategic planning.
Summary
- US 8,093,297 claims a formulation and therapeutic method for a specific derivative used in inflammatory disease treatment.
- Its scope is precise, focusing on chemical, formulation, and application specifics, with no claims covering broader classes.
- The patent landscape reveals a competitive environment centered on derivative chemistry, formulations, and combination therapy strategies.
- The patent remains enforceable until October 2029, after which generic competitors could explore development options.
Key Takeaways
- The patent’s narrow scope constrains its preventive power but simplifies potential design-around strategies.
- The patent landscape signals ongoing competition and innovation in chemical derivatives and drug delivery for autoimmune applications.
- Strategic licensing or collaboration might be necessary to navigate overlapping patent rights.
- The expiration date provides an upcoming opportunity for generic or biosimilar development.
- Regulatory and patent expiry timelines should inform clinical development plans.
FAQs
-
What is the primary innovation of US 8,093,297?
It covers a specific pharmaceutical composition, including a unique derivative and a controlled-release formulation for treating autoimmune diseases.
-
How broad are the claims in this patent?
The claims narrowly define both the chemical structure and delivery method, limiting generalization to other derivatives or routes.
-
Are there similar patents nearby in scope?
Yes, numerous patents focus on chemical derivatives of similar classes and controlled-release formulations, indicating active competition.
-
When does the patent expire?
October 2029, based on the filing date of September 2009.
-
What are potential risks for new entrants?
Overlapping claims in formulations and derivatives increase infringement risks; licensing or design-around strategies are advised.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 8,093,297. Retrieved from https://patents.google.com/patent/US8093297B2/
[2] Patent landscape analysis for autoimmune drug compositions. (2021). Journal of Pharmaceutical Innovation, 16(4), 512-528.
[3] Global Patent Database. (2023). Patent filings related to autoimmune disease therapies. Retrieved from https://globalpatentdatabase.com
